<?xml version="1.0" encoding="UTF-8"?>
<p id="p0180">SARS-CoV-2 can inhibit the endogenous secretion of IFN by host cells, thus in turn reducing their ability to suppress viral infections (
 <xref rid="bib17" ref-type="bibr">Cegolon et al, 2020</xref>). Therefore, the use of exogenous IFN is critical with the severe form of COVID-19 (
 <xref rid="bib84" ref-type="bibr">Zhou et al., 2020</xref>). A recent open-label prospective study tested nasal drops of recombinant human interferon alpha (rhIFN-α) on 2944 health care workers in China during SARS-CoV-2 epidemics as follows (
 <xref rid="bib50" ref-type="bibr">Meng et al., 2020</xref>):
 <list list-type="simple" id="ulist0010">
  <list-item id="u0010">
   <label>•</label>
   <p id="p0185">2415 subjects (997 doctors and 1418 nurses with average ages of 37.38 and 33.56 years respectively) included in a “low-risk group” were administered 2–3 drops/nostril/time of rhIFN-α, 4 times/day for 28 days.</p>
  </list-item>
  <list-item id="u0015">
   <label>•</label>
   <p id="p0190">529 subjects (122 doctors and 407 nurses with average ages of 35.24 and 32.16 years respectively) were included in a “high-risk group” and administered 2–3 drops/nostril/time of rhIFN-α, 4 times/day for 28 days, in addition to thymosin-α 11.6 mg hypodermic injection once a week.</p>
  </list-item>
 </list>
</p>
